Your browser doesn't support javascript.
loading
Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer.
Grinshpun, A; Ren, S; Graham, N; DeMeo, M K; Wrabel, E; Carter, J; Tayob, N; Pereslete, A; Hamilton, E; Juric, D; Mayer, E L; Tolaney, S M; Krop, I E; Metzger, O.
Afiliação
  • Grinshpun A; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston.
  • Ren S; Department of Data Science, Dana-Farber Cancer Institute, Boston.
  • Graham N; Department of Data Science, Dana-Farber Cancer Institute, Boston.
  • DeMeo MK; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston.
  • Wrabel E; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston.
  • Carter J; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston.
  • Tayob N; Harvard Medical School, Boston; Department of Data Science, Dana-Farber Cancer Institute, Boston.
  • Pereslete A; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston.
  • Hamilton E; Sarah Cannon Research Institute, Nashville; Breast and Gynecologic Research Program, Tennessee Oncology PLLC, Nashville.
  • Juric D; Harvard Medical School, Boston; Massachusetts General Hospital Cancer Center, Boston, USA.
  • Mayer EL; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston.
  • Tolaney SM; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston.
  • Krop IE; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston.
  • Metzger O; Breast Oncology Program, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston. Electronic address: otto_metzger@dfci.harvard.edu.
ESMO Open ; 9(6): 103465, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38833970
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Dose Máxima Tolerável Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Dose Máxima Tolerável Idioma: En Ano de publicação: 2024 Tipo de documento: Article